The FDA granted Rigel Pharmaceuticals (RIGL) orphan status for its treatment of myelodysplastic syndromes.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RIGL:
- Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald
- Rigel Pharmaceuticals price target lowered to $20 from $27 at B. Riley
- Rigel Pharmaceuticals announces initial data from Phase 1b study of R289
- Rigel Pharmaceuticals price target raised to $27 from $17 at B. Riley
- Rigel Pharmaceuticals announces R289 granted Fast Track designation by FDA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
